Tirzepatide – 60mg

Tirzepatide is a dual incretin peptide that simultaneously activates GLP-1 (glucagon-like peptide-1)
and GIP (glucose-dependent insulinotropic polypeptide) receptors. Its dual-agonist mechanism has
attracted attention for research into weight management, glycemic control, and lipid metabolism.
With a unique ability to influence multiple pathways, Tirzepatide is being widely studied as one
of the most promising peptides in modern metabolic research.

Potential Research Benefits

• Explored in obesity and weight reduction studies
• Studied for insulin sensitivity & glycemic control
• Potential role in lipid metabolism research
• Dual action on GLP-1 and GIP receptors

Scientific Background

By targeting both GLP-1 and GIP receptors, Tirzepatide has been shown in early studies to improve
satiety, reduce food intake, and enhance glucose homeostasis. Research indicates it may provide
synergistic benefits over single-agonist peptides, making it particularly effective in experimental
models of obesity and type 2 diabetes. Its dual incretin design makes it a cornerstone compound for
advanced metabolic studies.

Product Details

• Compound: Tirzepatide
• Form: Lyophilized Powder
• Amount: 60mg per vial
• Purity: ≥99%
• Appearance: White to off-white powder
• Research Use Only: Not for human consumption